Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Cortexyme

Cortexyme
2012 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
CRTX STOCK SYMBOL
$58.64 SHARE PRICE (As of Friday Closing)
Description

Cortexyme Inc is a clinical stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis, or P. gingivalis, and its secreted toxic virulence factor proteases, called gingipains.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 269 East Grand Avenue
  • Verily Campus
  • South San Francisco, CA 94080
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Cortexyme’s full profile, request a free trial.

Cortexyme Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$19.35 - $72.94 $1.57B $62.62 -$1.75 177K 26.9M

Cortexyme Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
Enterprise Value 540,862
Revenue 0 0 0
EBITDA (29,925) (12,274) (10,547)
Net Income (28,071) (12,476) (12,235)
Total Assets 133,414 72,878 7,718
Total Debt 0 0 7,171
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cortexyme Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Cortexyme‘s full profile, request access.

Request full access to PitchBook

Cortexyme Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Cortexyme‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Cortexyme Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alector Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 0 000.00
00000000 000000000 Venture Capital-Backed Cambridge, MA 00 000.00 0000000000 0 000.00
00000 000000000000 Formerly VC-backed Cambridge, MA 000.00 000000&0 000.00
0000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
To view this company’s complete list of competitors, request access »

Cortexyme Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Cortexyme‘s full profile, request access.

Request full access to PitchBook

Cortexyme Executive Team (12)

Name Title Board
Seat
Contact
Info
Casey Lynch Chief Executive Officer & Chairman
Christopher Lowe Chief Financial Officer & Treasurer
Chris Lowe Chief Financial Officer
Stephen Dominy MD Chief Scientific Officer & Board Member
Leslie Holsinger Ph.D Executive Vice President

3 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Cortexyme Board Members (10)

Name Representing Role Since Contact
Info
Casey Lynch Cortexyme Chief Executive Officer & Chairman 000 0000
Christopher Senner Cortexyme Board Member 000 0000
David Lamond Lamond Capital Partners Board Member 000 0000
Kevin Young Cortexyme Board Member 000 0000
Margi McLoughlin Pfizer Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 10 board members. Get the full list »